Cmed Appoints Andrew Kellett as Chief Financial
Officer
Clinical Research and Data Solutions Leader Aids Growth with New Hire
September 08, 2010 06:53 AM Eastern Daylight Time
HORSHAM, England--(EON: Enhanced Online News)--Cmed Group which combines clinical research services
with a leading-edge clinical data capture and management system, has strengthened its senior management team with
the appointment of Andrew Kellett as Chief Financial Officer (CFO).
Kellett, who was formerly Finance Director of Genetix Group Plc, a global life sciences diagnostics and digital
pathology company, brings on board a wealth of experience in the financial management of international high growth
companies in the medical sector.
His appointment strengthens Cmed’s management team as the group accelerates the global expansion of its flagship
IT product Timaeus, a next-generation clinical data capture and management solution which is already delivering
critical benefits in a number of major international clinical trials.
Kellett spent four years as CFO at Genetix which was acquired by the Danaher Corporation this year for £63 million
and prior to that he was European Finance Director and Global Controller for clinical trials and pharmaceutical
business development for US-based Quest Diagnostics Inc, a world-leading diagnostic lab testing company.
He trained at Coopers and Lybrand and has established a strong track record in financial management, operational
leadership in diverse, global companies, as well as extensive experience in driving strategic growth, corporate
development activities, mergers and acquisitions.
Cmed Chief Executive David Connelly said: “We are delighted to welcome Andrew Kellett to the Cmed team.
Andrew joins at a pivotal moment in Cmed’s growth and development and brings a wealth of experience in global
financial operations and strategy. Andrew’s expertise and knowledge of the financial arena will play an essential part
in helping us achieve our goals.”
Kellett commented: "I a